Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
83.58
+2.79 (3.45%)
At close: Jun 15, 2026, 4:00 PM EDT
83.18
-0.40 (-0.48%)
After-hours: Jun 15, 2026, 7:15 PM EDT
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
7.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.14B |
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Praxis Precision Medicines | 7.46M |
| ABIVAX Société Anonyme | 5.67M |
SYRE News
- 7 hours ago - Spyre Therapeutics price target raised to $112 from $98 at BTIG - TheFly
- 14 hours ago - Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
- 14 hours ago - Spyre Therapeutics announces SKYLINE trial achieves primary endpoint - TheFly
- 15 hours ago - Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire
- 4 days ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 7 days ago - Spyre Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 11 days ago - Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank - TheFly